Selected research
Industry Research
Saxagliptin Industry Research Report 2026
Market perspective
The global Saxagliptin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Saxagliptin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Saxagliptin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Saxagliptin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Saxagliptin include Bristol-Myers Squibb Company, Minxiang Pharma, Taizhou Canova Bio-technology, Tapi Teva, AstraZeneca, Hebei Kangtai Pharma, Huaman Xincaiiao Keji and Tianjin Scipharmacn, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Saxagliptin market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Saxagliptin Market by Company
Bristol-Myers Squibb Company
Minxiang Pharma
Taizhou Canova Bio-technology
Tapi Teva
AstraZeneca
Hebei Kangtai Pharma
Huaman Xincaiiao Keji
Tianjin Scipharmacn
Saxagliptin Segment by Type
2.5mg
5mg
Saxagliptin Segment by Application
Hospital
Clinic
Others
Saxagliptin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Saxagliptin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Saxagliptin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Saxagliptin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Saxagliptin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Saxagliptin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Saxagliptin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 2.5mg
- 5mg
Applications
- Hospital
- Clinic
- Others
Companies covered
- Bristol-Myers Squibb Company
- Minxiang Pharma
- Taizhou Canova Bio-technology
- Tapi Teva
- AstraZeneca
- Hebei Kangtai Pharma
- Huaman Xincaiiao Keji
- Tianjin Scipharmacn
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Saxagliptin Market Size (2021-2032)
- 2.2.2 Global Saxagliptin Sales (2021-2032)
- 2.2.3 Global Saxagliptin Market Average Price (2021-2032)
- 2.3 Saxagliptin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 2.5mg
- 2.3.3 5mg
- 2.4 Saxagliptin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Saxagliptin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Saxagliptin Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Saxagliptin Revenue of Manufacturers (2021-2026)
- 3.4 Global Saxagliptin Average Price by Manufacturers (2021-2026)
- 3.5 Global Saxagliptin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Saxagliptin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Saxagliptin, Product Type & Application
- 3.8 Global Manufacturers of Saxagliptin, Established Date
- 3.9 Global Saxagliptin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bristol-Myers Squibb Company
- 4.1.1 Bristol-Myers Squibb Company Company Information
- 4.1.2 Bristol-Myers Squibb Company Business Overview
- 4.1.3 Bristol-Myers Squibb Company Saxagliptin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bristol-Myers Squibb Company Saxagliptin Product Portfolio
- 4.1.5 Bristol-Myers Squibb Company Recent Developments
- 4.2 Minxiang Pharma
- 4.2.1 Minxiang Pharma Company Information
- 4.2.2 Minxiang Pharma Business Overview
- 4.2.3 Minxiang Pharma Saxagliptin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Minxiang Pharma Saxagliptin Product Portfolio
- 4.2.5 Minxiang Pharma Recent Developments
- 4.3 Taizhou Canova Bio-technology
- 4.3.1 Taizhou Canova Bio-technology Company Information
- 4.3.2 Taizhou Canova Bio-technology Business Overview
- 4.3.3 Taizhou Canova Bio-technology Saxagliptin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Taizhou Canova Bio-technology Saxagliptin Product Portfolio
- 4.3.5 Taizhou Canova Bio-technology Recent Developments
- 4.4 Tapi Teva
- 4.4.1 Tapi Teva Company Information
- 4.4.2 Tapi Teva Business Overview
- 4.4.3 Tapi Teva Saxagliptin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Tapi Teva Saxagliptin Product Portfolio
- 4.4.5 Tapi Teva Recent Developments
- 4.5 AstraZeneca
- 4.5.1 AstraZeneca Company Information
- 4.5.2 AstraZeneca Business Overview
- 4.5.3 AstraZeneca Saxagliptin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AstraZeneca Saxagliptin Product Portfolio
- 4.5.5 AstraZeneca Recent Developments
- 4.6 Hebei Kangtai Pharma
- 4.6.1 Hebei Kangtai Pharma Company Information
- 4.6.2 Hebei Kangtai Pharma Business Overview
- 4.6.3 Hebei Kangtai Pharma Saxagliptin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hebei Kangtai Pharma Saxagliptin Product Portfolio
- 4.6.5 Hebei Kangtai Pharma Recent Developments
- 4.7 Huaman Xincaiiao Keji
- 4.7.1 Huaman Xincaiiao Keji Company Information
- 4.7.2 Huaman Xincaiiao Keji Business Overview
- 4.7.3 Huaman Xincaiiao Keji Saxagliptin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Huaman Xincaiiao Keji Saxagliptin Product Portfolio
- 4.7.5 Huaman Xincaiiao Keji Recent Developments
- 4.8 Tianjin Scipharmacn
- 4.8.1 Tianjin Scipharmacn Company Information
- 4.8.2 Tianjin Scipharmacn Business Overview
- 4.8.3 Tianjin Scipharmacn Saxagliptin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Tianjin Scipharmacn Saxagliptin Product Portfolio
- 4.8.5 Tianjin Scipharmacn Recent Developments
5 Global Saxagliptin Market Scenario by Region
- 5.1 Global Saxagliptin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Saxagliptin Sales by Region: 2021-2032
- 5.2.1 Global Saxagliptin Sales by Region: 2021-2026
- 5.2.2 Global Saxagliptin Sales by Region: 2027-2032
- 5.3 Global Saxagliptin Revenue by Region: 2021-2032
- 5.3.1 Global Saxagliptin Revenue by Region: 2021-2026
- 5.3.2 Global Saxagliptin Revenue by Region: 2027-2032
- 5.4 North America Saxagliptin Market Facts & Figures by Country
- 5.4.1 North America Saxagliptin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Saxagliptin Sales by Country (2021-2032)
- 5.4.3 North America Saxagliptin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Saxagliptin Market Facts & Figures by Country
- 5.5.1 Europe Saxagliptin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Saxagliptin Sales by Country (2021-2032)
- 5.5.3 Europe Saxagliptin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Saxagliptin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Saxagliptin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Saxagliptin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Saxagliptin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Saxagliptin Market Facts & Figures by Country
- 5.7.1 South America Saxagliptin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Saxagliptin Sales by Country (2021-2032)
- 5.7.3 South America Saxagliptin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Saxagliptin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Saxagliptin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Saxagliptin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Saxagliptin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Saxagliptin Sales by Type (2021-2032)
- 6.1.1 Global Saxagliptin Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Saxagliptin Sales Market Share by Type (2021-2032)
- 6.2 Global Saxagliptin Revenue by Type (2021-2032)
- 6.2.1 Global Saxagliptin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Saxagliptin Revenue Market Share by Type (2021-2032)
- 6.3 Global Saxagliptin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Saxagliptin Sales by Application (2021-2032)
- 7.1.1 Global Saxagliptin Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Saxagliptin Sales Market Share by Application (2021-2032)
- 7.2 Global Saxagliptin Revenue by Application (2021-2032)
- 7.2.1 Global Saxagliptin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Saxagliptin Revenue Market Share by Application (2021-2032)
- 7.3 Global Saxagliptin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Saxagliptin Value Chain Analysis
- 8.1.1 Saxagliptin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Saxagliptin Production Mode & Process
- 8.2 Saxagliptin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Saxagliptin Distributors
- 8.2.3 Saxagliptin Customers
9 Global Saxagliptin Analyzing Market Dynamics
- 9.1 Saxagliptin Industry Trends
- 9.2 Saxagliptin Industry Drivers
- 9.3 Saxagliptin Industry Opportunities and Challenges
- 9.4 Saxagliptin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst